1. Home
  2. CWEN vs ACAD Comparison

CWEN vs ACAD Comparison

Compare CWEN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearway Energy Inc. Class C

CWEN

Clearway Energy Inc. Class C

HOLD

Current Price

$39.76

Market Cap

4.5B

Sector

Utilities

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.03

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CWEN
ACAD
Founded
2012
1993
Country
United States
United States
Employees
60
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CWEN
ACAD
Price
$39.76
$22.03
Analyst Decision
Strong Buy
Buy
Analyst Count
8
22
Target Price
$42.00
$30.55
AVG Volume (30 Days)
702.3K
1.5M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
4.68%
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
N/A
$726,437,000.00
Revenue This Year
$16.38
$18.80
Revenue Next Year
$8.48
$11.70
P/E Ratio
$17.06
$9.61
Revenue Growth
N/A
40.45
52 Week Low
$27.67
$14.18
52 Week High
$41.51
$28.35

Technical Indicators

Market Signals
Indicator
CWEN
ACAD
Relative Strength Index (RSI) 53.20 49.63
Support Level $36.30 $20.81
Resistance Level $40.11 $22.03
Average True Range (ATR) 1.11 0.62
MACD -0.19 0.07
Stochastic Oscillator 56.08 52.89

Price Performance

Historical Comparison
CWEN
ACAD

About CWEN Clearway Energy Inc. Class C

Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: